Previous 10 | Next 10 |
Y-mAbs Therapeutics ( NASDAQ: YMAB ) said the U.S. Food and Drug Administration (FDA) cleared its application to start a phase 1 multicenter basket trial for GD2-SADA targeting malignant melanoma, sarcoma and small cell lung cancer. The trial will have three parts and ...
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the tr...
The following slide deck was published by Y-mAbs Therapeutics, Inc. in conjunction with this event. For further details see: Y-mAbs Therapeutics (YMAB) Investor Presentation
The U.S. Food and Drug Administration granted priority review to Y-mAbs Therapeutics's (NASDAQ:YMAB) application seeking approval of Omblastys (omburtamab) to treat children with CNS/leptomeningeal metastasis from neuroblastoma. The FDA is expected to make a decision on the bio...
NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the tre...
YMAB has one approved drug and another coming up in an ultra rare disease. Approval looks likely given the lower threshold for such diseases, and strong data supporting the application. The markets are small, but there's not a lot of competition. For further details see: ...
Y-mAbs Therapeutics' (NASDAQ:YMAB) humanized anti-GD2 antibody naxitamab, in combination with other oncologics, met its primary endpoint in a phase 2 trial of patients with chemoresistant high-risk neuroblastoma. Objective response rate, the primary endpoint, was 30.6% in a cohort of patients...
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for t...
The following slide deck was published by Y-mAbs Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Y-mAbs Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation
Y-mAbs Therapeutics press release (NASDAQ:YMAB): Q1 GAAP EPS of -$0.64 beats by $0.08. Revenue of $10.49M (+94.3% Y/Y) misses by $0.61M. For further details see: Y-mAbs Therapeutics GAAP EPS of -$0.64 beats by $0.08, revenue of $10.49M misses by $0.61M
News, Short Squeeze, Breakout and More Instantly...
Y-mAbs Therapeutics Inc. Company Name:
YMAB Stock Symbol:
NASDAQ Market:
Y-mAbs Therapeutics Inc. Website:
2024-07-05 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic pr...
Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 millio...